In this issue:
Leukaemia selection
- Oral azacitidine maintenance for AML in first remission
- Fixed-duration, MRD-guided approach in CLL
- Novel DHODH inhibitor for treating myeloid malignancies
- Impact of cytogenetic risk on HSCT outcomes in relapsed/ refractory AML
- Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1-mutated AML
- Clinical characteristics and outcomes of AML with both FLT3-ITD and IDH mutations
Lymphoma selection
- Long-term results of PETguided RT in advanced-stage DLBCL treated with R-CHOP
- Pembrolizumab then AVD in untreated early unfavourable and advanced classical HL
- Lenalidomide maintenance after autologous HSCT in mantle cell lymphoma
- PET-guided omission of RT in early-stage unfavourable HL
Please login below to download this issue (PDF)